# Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)

> **NCT06534723** · PHASE3 · RECRUITING · sponsor: **Sichuan Jishengtang Pharmaceutical Co., Ltd.** · enrollment: 570 (estimated)

## Conditions studied

- Alzheimer's Dementia

## Interventions

- **DRUG:** Wujia Yizhi granules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06534723
- **Lead sponsor:** Sichuan Jishengtang Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-20
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-01
- **Target enrollment:** 570 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06534723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06534723, "Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06534723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*